摘要
目的:联合检测血清中AFP,GGT-II,sICAM-1以提高肝细胞性肝癌(HCC)的确诊率.方法:46例HCC患者,肝转移癌18例,肝硬化42例,各型肝炎30例,良性肝肿瘤38例及健康对照者46例.血清AFP,GGT-II及sICAM-1分别采用荧光酶联免疫吸附法、自然不连续缓冲系统聚丙烯酰胺凝胶垂直电泳检测法和双抗体酶联免疫吸附法进行检测.结果:AFP,GGT-II,sICAM-1三者联合检测使HCC的检出灵敏度达到96%,正确率达到93%,高于单独检测其中任一肿瘤标志物,可明显降低漏诊概率.结论:肿瘤标志物的联合检测对确诊肝细胞性肝癌具有临床价值.
AIM： To enhance the final diagnosis rate of hepatocellular carcinoma （HCC） by detecting AFP, GGT-Ⅱ and sICAM-1 consociatedly in HCC sufferers＇ sera. METHODS： We collected altogether 220 blood samples, including 46 cases of HCC, 18 cases of liver metastatic carcinoma, 38 cases of liver benign tumor, 42 cases of hepatic cirrhosis, 30 cases of hepatitis and 46 cases of normal controls. The serum AFP, GGT-Ⅱ, sICAM-1 were measued with fluorescent enzyme linked immunosorbent assay, vertical polyacrylamide gel gradient electrophoresis and double antibody enzyme linked immunosorbent assay. RESULTS： Combined detection of AFP, GGT-Ⅱ and sICAM-1 enhanced the sensitivity of HCC diagnosis to 96% and the accuracy to 93%, higher than that of detection of any single tumor marker and obviously reduced the rate of misdiagnosis. CONCLUSION： It is necessary to detect the markers of HCC consociatedly.
出处
《第四军医大学学报》
北大核心
2008年第5期465-467,共3页
Journal of the Fourth Military Medical University
